ovarian cancer
Conditions
Interventions
Experimental group:Paclitaxel for injection (albumin bound) 260 mg/m2, d1, Carboplatin injection AUC 5~6, d1, 21 days in one cycle, 6 cycles in total.
Sponsors
Medical University Affiliated Tumor Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Female, aged 18 to 75 years; 2) Histological or cytological confirmation of Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; 3) Newly diagnosed Stage III-IV disease according to International Federation of Gynecology and Obstetrics (FIGO) stage; 4) At least one measurable objective lesion (both primary and metastatic) was identified based on the RECIST1.1 criteria; 5) ECOG performance status 0-2; 6) Expected survival time more than 3 months; 7) Bone marrow function: Neutrophils >= 1.5 x10^9/L, platelets >= 100 x 10^9/L, hemoglobin >= 90 g/L; Serum creatinine <= 1.5x ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)<= 2.5x ULN or when liver metastases occur<= 5x ULNTotal bilirubin <= 2.5 x ULN; 8) There was no second tumor within 5 years, except for cured Basal cell carcinoma or squamous cell carcinoma of skin or carcinoma; in situ at any other site. 9) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Patients with low malignant potential ovarian tumors; 2) Received systemic antitumor therapy for ovarian cancer (Patients with previous chemotherapy, monoclonal antibodies, tyrosine kinase inhibitors or hormones, abdominal or pelvic radiotherapy); 3) Have other malignant tumors within 5 years, except melanoma skin cancer or cervical cancer in situ; 4) These who were suffer from uncontrolled serious medical disease that researchers believe will affect the treatment of uncontrolled serious medical disease. For example, serious medical diseases, including serious heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer and so on; 5) Known to be allergic, highly sensitive or intolerable to research-related drugs or excipients; 6) Receive chemotherapy within 30 days before the first chemotherapy; 7) Patients who were unsuitable for this study judged by investigators; 8) Female patients who are pregnant or lactating; those of childbearing age who refuse to accept contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactLi Li
Medical University Affiliated Tumor Hospital
Outcome results
None listed